Hypereosinophilic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 66 pages | ID: HEC7EC70AF04EN
Global Markets Direct

Abstracts

Hypereosinophilic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2022, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.

The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (? 1500 eosinophils/mm?) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow. HES is a diagnosis of exclusion, after clonal eosinophilia (such as leukemia) and reactive eosinophilia (in response to infection, autoimmune disease, atopy, hypoadrenalism, tropical eosinophilia, or cancer) have been ruled out.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 3, 3 and 1 respectively.

Hypereosinophilic Syndrome (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypereosinophilic Syndrome (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hypereosinophilic Syndrome - Overview
Hypereosinophilic Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypereosinophilic Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
Hypereosinophilic Syndrome - Drug Profiles
Hypereosinophilic Syndrome - Dormant Projects
Hypereosinophilic Syndrome - Product Development Milestones
Featured News & Press Releases
Nov 17, 2021: European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases
Sep 17, 2021: GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil-driven diseases
Sep 15, 2021: NUCALA (mepolizumab) approved in Canada as the first and only biologic treatment for adults with hypereosinophilic syndrome
Jan 15, 2021: Knopp Biosciences reports positive trial results of oral asthma drug
Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
Sep 28, 2020: GSK’s Nucala receives FDA approval to treat HES
Sep 16, 2020: Knopp Biosciences completes enrollment in phase 2 trial of oral dexpramipexole in eosinophilic asthma
May 27, 2020: FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
Dec 03, 2019: Knopp to start trial enrollment of oral dexpramipexole in H1 2020
Nov 14, 2019: GSK reports positive data for Nucala in late-stage HES trial
Aug 19, 2019: Knopp begins study of dexpramipexole in eosinophilic asthma patients
Jul 09, 2019: Knopp Biosciences to present clinical data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Apr 24, 2019: Knopp Biosciences receives FDA Orphan Drug Designation for Dexpramipexole for treatment of Hypereosinophilic Syndrome
Apr 05, 2019: Study finds AstraZeneca’s asthma drug could treat immune disorder
Apr 03, 2019: FDA-approved drug effectively treats rare chronic immune disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypereosinophilic Syndrome, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypereosinophilic Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
Hypereosinophilic Syndrome - Pipeline by Areteia Therapeutics Inc, 2022
Hypereosinophilic Syndrome - Pipeline by GSK plc, 2022
Hypereosinophilic Syndrome - Pipeline by Incyte Corp, 2022
Hypereosinophilic Syndrome - Pipeline by Kyowa Kirin Co Ltd, 2022
Hypereosinophilic Syndrome - Pipeline by Nexeos Bio, 2022
Hypereosinophilic Syndrome - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypereosinophilic Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022